Provectus Biopharmaceutica-a (PVCT) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

PVCT ranks #12683 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

4 institutions disclose a position in PVCT, but none treat it as a major bet — even Home Federal Bank Of Tennessee, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

PVCT reported a net loss of $4.7M over the trailing twelve months.

• Not yet profitable — net loss of $4.7M over the trailing twelve months
• Revenue declined 45.5% year over year
• Net income improved year over year, from -$6.3M to -$4.7M
• Operating cash flow was negative, using $3.3M in cash
• Current ratio of 0.08x — below the conventional 1.5x liquidity buffer
• Liabilities run 16.66x equity — a highly leveraged balance sheet worth noting